Clinical and Biochemical Effect of Aminoglutethimide in the Treatment of Advanced Prostatic Carcinoma

Publisher Website
Google Scholar
Abstract
Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, .apprx. 20% of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1000 mg aminoglutethimide and 40 mg hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project [USA]. One patient has had a complete response and is in remission after 275 wk of therapy. A partial response was noted in 4 patients; the disease was objectively stable in 6. Pretreatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (P < 0.01). Response and drug toxicity are discussed.